Synonym: 4-(2-Chlorophenyl)-1-ethyl-1,4-dihydro-6-methyl-2,3,5-pyridinetricarboxylic acid 5-isopropyl ester disodium salt hydrate
CAS Number: 114290-51-6 (anhydrous)
Empirical Formula (Hill Notation): C20H20ClNNa2O6 · xH2O
Molecular Weight: 451.81 (anhydrous basis)
MDL Number: MFCD08705410
Linear Formula: C20H20ClNNa2O6 · xH2O
Product Type: Chemical
assay |
≥98% (HPLC) |
color |
white |
form |
solid |
InChI |
1S/C20H22ClNO6.2Na.H2O/c1-5-22-11(4)14(20(27)28-10(2)3)15(12-8-6-7-9-13(12)21)16(18(23)24)17(22)19(25)26;;;/h6-10,15H,5H2,1-4H3,(H,23,24)(H,25,26);;;1H2/q;2*+1;/p-2 |
InChI key |
QECLOEJXLYHXNF-UHFFFAOYSA-L |
originator |
Bayer |
Quality Level |
100 |
SMILES string |
[Na+].[Na+].[H]O[H].CCN1C(C)=C(C(c2ccccc2Cl)C(C([O-])=O)=C1C([O-])=O)C(=O)OC(C)C |
solubility |
H2O: >8 mg/mL |
storage condition |
protect from light |
storage temp. |
2-8°C |
Biochem/physiol Actions: |
BAY W1807, the active metabolite of BAY R3401, inhibits muscle glycogen phosphorylase a and b. In gel-filtered liver extracts, racemic BAY U6751 (containing active BAY W1807) was tested for inhibition of phosphorylase in the glycogenolytic (in which only phosphorylase a is active). In liver extracts, BAY U6751 (0.9-36 μmol/L) inhibited glycogen synthesis by phosphorylase b (notwithstanding the inclusion of AMP), but not by phosphorylase a. Inhibition of phosphorylase-a-catalyzed glycogenolysis was partially relieved by AMP (500 μmol/L). BAY U6751 facilitated phosphorylase-a dephosphorylation. Isolated hepatocytes and perfused livers were tested for BAY R3401-induced changes in phosphorylase-a:b ratios and glycogenolytic output. |
Caution: |
Light sensitive. Store in amber vials. |
Features and Benefits: |
This compound was developed by Bayer . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
Packaging: |
5, 25 mg in glass bottle |
Purity |
≥98% (HPLC) |
Storage Temp. |
2-8°C |
UNSPSC |
12352200 |